Journey Medical (NASDAQ:DERM) Posts Earnings Results, Beats Expectations By $0.02 EPS

Journey Medical (NASDAQ:DERM) released its quarterly earnings results on Wednesday. The company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.02, FiscalAI reports. The business had revenue of $16.08 million for the quarter, compared to analyst estimates of $18.86 million. Journey Medical had a negative net margin of 18.48% and a negative return on equity of 51.42%.

Here are the key takeaways from Journey Medical’s conference call:

• EMROSI achieved ~53,000 prescriptions in nine months, Q4 scripts rose ~50% sequentially, and >3,500 unique prescribers drove an exit annualized run-rate above 126,000 scripts.
• Full‑year 2025 revenue was $61.9M (+10%), gross margin improved to 66.2%, GAAP net loss narrowed to $11.4M, and the company reported positive adjusted EBITDA of $2.9M while ending the year with ~$24.1M cash.
• Market access is progressing—~100 million commercial covered lives and contracts with two of the top three GPOs (third expected soon)—but downstream payer formulary timing means prescription demand currently outpaces recognized revenue.
• Legacy products, notably the Accutane franchise, faced pressure from generic competition, weighing on the base business revenue in 2025.
• Management expects to remain adjusted EBITDA positive in 2026, plans a modest salesforce increase and the launch of one to two additional dermatology products, and sees reimbursement gains as the key driver of revenue conversion this year.

Journey Medical Stock Down 2.9%

Shares of Journey Medical stock traded down $0.14 on Friday, hitting $4.64. 172,559 shares of the company traded hands, compared to its average volume of 174,546. Journey Medical has a 12-month low of $4.51 and a 12-month high of $9.56. The company has a quick ratio of 1.12, a current ratio of 1.42 and a debt-to-equity ratio of 0.75. The company has a market cap of $154.35 million, a PE ratio of -9.93 and a beta of 0.81. The company has a 50-day moving average price of $8.00 and a 200 day moving average price of $7.80.

Key Stories Impacting Journey Medical

Here are the key news stories impacting Journey Medical this week:

• Positive Sentiment: Strong early adoption of Emrosi — management reported Emrosi net revenue of $14.7M in FY2025 with ~53,000 prescriptions filled and payer access covering over 100M U.S. commercial lives, supporting a path to higher revenue and margin expansion. Full-Year 2025 Financial Results and Recent Corporate Highlights
• Positive Sentiment: Q4 EPS beat — reported EPS of ($0.04) beat consensus of ($0.06), indicating better-than-expected per-share performance despite top-line pressure. Q4 2025 Earnings – MarketBeat
• Positive Sentiment: HC Wainwright remains bullish — the firm kept a Buy rating and a $13 price target and published multi-year EPS ramp forecasts (FY2026–FY2030 growth to ~$2.01), signaling analyst conviction in recovery/scale. HC Wainwright Buy Rating and $13 Target (summary)
• Neutral Sentiment: Full-year revenue growth — FY2025 revenues were $61.9M vs $56.1M a year earlier, showing growth but still early in commercialization. Full-Year 2025 Financial Results and Recent Corporate Highlights
• Neutral Sentiment: Earnings call/transcripts available — management provided guidance commentary and pipeline/coverage updates on the March 25 call; review the transcript for color on payer uptake and margin timing. Q4 2025 Earnings Call Transcript
• Negative Sentiment: Revenue miss — Q4 revenue was $16.08M versus analyst estimates of $18.86M, highlighting slower-than-expected commercial traction in the quarter and pressuring near-term valuation. Q4 2025 Results and Call
• Negative Sentiment: Margins and profitability remain a concern — Journey shows negative net margin and ROE on recent results, and HC Wainwright trimmed several out-year EPS forecasts slightly, underlining execution and scaling risks. (See HC Wainwright note for estimates.)

Institutional Trading of Journey Medical

A number of institutional investors have recently bought and sold shares of DERM. Jane Street Group LLC purchased a new position in Journey Medical in the first quarter valued at about $110,000. Geode Capital Management LLC raised its stake in shares of Journey Medical by 130.7% during the 2nd quarter. Geode Capital Management LLC now owns 262,353 shares of the company’s stock worth $1,884,000 after purchasing an additional 148,612 shares in the last quarter. Creative Planning lifted its holdings in shares of Journey Medical by 178.5% during the 2nd quarter. Creative Planning now owns 32,764 shares of the company’s stock valued at $235,000 after buying an additional 21,000 shares during the last quarter. JPMorgan Chase & Co. acquired a new stake in shares of Journey Medical during the 2nd quarter valued at about $41,000. Finally, New York State Common Retirement Fund bought a new stake in shares of Journey Medical in the 2nd quarter valued at approximately $103,000. Institutional investors and hedge funds own 7.25% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have issued reports on DERM. HC Wainwright reissued a “buy” rating and set a $13.00 target price on shares of Journey Medical in a research note on Thursday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Journey Medical in a report on Wednesday, January 21st. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $13.00.

Journey Medical Company Profile

Journey Medical Corp, headquartered in Fairfield, New Jersey, is a commercial dermatology company focused on acquiring, developing and marketing prescription dermatology products in the United States. Since its incorporation in 2019, the company has built a portfolio of both branded and generic topical therapies designed to address a range of skin conditions, including acne, atopic dermatitis, fungal infections and inflammatory lesions.

The company’s product lineup features antibiotic/anti-inflammatory combinations and corticosteroid-based formulations delivered through proprietary gel, cream and foam vehicles.